Date:4/25/2012

could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to:  risks related to our assumptions of the repeatability of clinical results obtained using the new Masimo Pronto-7 and noninvasive sensor sizes, risks related to our belief that the Pronto-7 enables quick and easy noninvasive spot-checking of hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index at the point-of-care for all patients, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Media Contact:
Mike Drummond
Masimo Corporation
Phone: (949) 297-7434
Email: mdrummond@masimo.com

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Ox
'/>"/>

SOURCE Masimo Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Essential Medical Dismisses Patent Case against Masimo and Cercacor
2. New Study Shows Masimos Noninvasive Pleth Variability Index Provides Similar Ability to Assess Fluid Responsiveness During Surgery as More Costly and Invasive Method
3. Masimo to Report First Quarter 2012 Financial Results after Market Close on May 2
4. Fortis Healthcare Signs Agreement Giving Indias Fastest-Growing Hospital Chain Access to Masimos State-of-the-Art Noninvasive Patient Monitoring Solutions
5. Masimo to Present at 24th Annual ROTH Conference
6. Masimo Reports Fourth Quarter and Full Year 2011 Financial Results; Provides 2012 Financial Guidance
7. Masimo Announces "Better Care" Program - A Hospital Risk-Share Program for Blood Transfusion Related Cost Reduction with SpHb®, and $30 SpHb Sensor Price
8. Masimo to Report Fourth Quarter and Full Year 2011 Financial Results After Market Close on February 14, 2012
9. New Clinical Study Presented at the NYPGA Meeting Shows Respiration Rate Monitoring -- Considered the Fourth Primary Vital Sign -- Has Been Revolutionized With Masimo rainbow Acoustic Monitoring Technology
10. Shands Jacksonville Medical Center Converts to Masimo rainbow SET for State-of-the-Art Noninvasive Patient Monitoring Capabilities
11. Masimo to Present at Lazard Capital Markets Healthcare Conference